ACIU

Announcements

Nothing here yet

Daily updates

• AC Immune reported favorable Week 100 Part 1 Phase 2 VacSYn results for ACI-7104 in early-stage Parkinson's disease, meeting primary safety, tolerability, and immunogenicity criteria.Sep 23, 2026

FDA designations

Nothing here yet

News

• AC Immune reports positive safety and immunogenicity results at Week 100 from Part 1 of the Phase 2 VacSYn trial of ACI-7104Sep 23, 2026
• AC Immune announced positive preliminary Phase 1 data for its NLRP3 inhibitor ACI-19764Aug 20, 2026
• AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24Jul 1, 2026
• AC Immune initiated the final cohort in the Phase 1b/2 ABATE trial for Alzheimer’s immunotherapyApr 30, 2026
• AC Immune announces positive interim Phase 2 data for ACI-7104.056 supporting Parkinson's progression slowingDec 11, 2025